Immunotherapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in anticancer therapy. Part 2. Clinical aspects
Medical academic journal · 24.03.2026 · 26 (1) · 46-57
DOI: 10.17816/maj641690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical academic journal, online erschienen am 24.03.2026. Verfasst von Andrei A. Shukshin und 4 weiteren Autor:innen. Die Arbeit nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Therapy targeting immune checkpoint (IC) inhibition is an effective treatment for various cancers, including melanoma, non-small cell lung cancer, renal cell carcinoma, prostate cancer, and many others. This type of immunotherapy aims to inhibit/block the signaling molecules PD-1 and CTLA-4, which play an important role in regulating immune responses. The primary effect of monoclonal antibodies directed against CTLA-4 is depletion of the T-regulatory cell pool, which increases the co-stimulatory signal from CD28 on the surface of T-lymphocytes and, consequently, activates T-cells involved in destroying tumor clones. Blockade of PD-1 and/or its ligands (PD-L1 and PD-L2) increases the antitumor activity of T-lymphocytes and NK-cells. The use of immune checkpoint inhibitors can cause a wide range of adverse events in patients, including toxic hepatitis, pneumonitis, hypophysitis, myocarditis, myositis, nephritis, neurotoxicity, adrenal insufficiency, hematotoxicity, and many others. However, despite the serious side effects of ICIs, the antitumor activity of these drugs outweighs the potential adverse events. Moreover, most adverse reactions are well controlled, and serious side effects can be diagnosed early and prevented from developing. Thus, immune checkpoint blockade is an effective treatment for many malignancies, but many aspects still require optimization depending on the individual patient characteristics.
Zitieren
APA
Shukshin, A. A., Rubinstein, A. A., Golovkin, A. S., Moiseeva, O. M., & Kudriavtsev, I. V. (2026). Immunotherapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in anticancer therapy. Part 2. Clinical aspects. Medical academic journal, 26(1), 46-57. https://doi.org/10.17816/maj641690
Vancouver
Shukshin AA, Rubinstein AA, Golovkin AS, Moiseeva OM, Kudriavtsev IV. Immunotherapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in anticancer therapy. Part 2. Clinical aspects. Medical academic journal. 2026;26(1):46-57. doi:10.17816/maj641690
BibTeX
@article{Shukshin2026,
author = {Shukshin, Andrei A. and Rubinstein, Artem A. and Golovkin, Alexey S. and Moiseeva, Olga M. and Kudriavtsev, Igor V.},
title = {Immunotherapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in anticancer therapy. Part 2. Clinical aspects},
journal = {Medical academic journal},
year = {2026},
volume = {26},
number = {1},
pages = {46--57},
doi = {10.17816/maj641690}
}
EUVIMED